Weighted Prevalence in the Use of Prescription Medications in the Previous 30 Days by Therapeutic Drug Class Among Children and Adolescents in the United States, Overall and by Gender and Age Group (2013–2014)
. | Prevalence of Use, % (95% CI) . | ||||||
---|---|---|---|---|---|---|---|
Overall, n = 4404 . | 0–5 y . | 6–12 y . | 13–19 y . | ||||
Girls (n = 775) . | Boys (n = 828) . | Girls (n = 746) . | Boys (n = 817) . | Girls (n = 640) . | Boys (n = 598) . | ||
Respiratory agents | 6.8 (5.8–8.0) | 3.9 (2.3–6.6) | 5.1 (3.3–7.8)** | 5.7 (4.1–8.0) | 11.5 (8.9–14.7)* | 6.4 (4.2–9.7) | 7.0 (4.9–9.9) |
Bronchodilators | 3.5 (3.0–4.1) | 2.7 (1.5–4.7) | 2.7 (1.5–4.8) | 3.0 (1.7–5.5) | 5.5 (4.3–6.9)* | 3.4 (1.7–7.0)a | 3.2 (2.1–5.0) |
Albuterol | 3.0 (2.5–3.6) | 2.6 (1.5–4.5) | 2.5 (1.4–4.5) | 2.6 (1.4–4.8) | 4.5 (3.1–6.6) | 3.1 (1.4–6.9)a | 2.6 (1.8–3.6) |
Levalbuterol | 0.3 (0.1–0.6)a | 0.2 (0.0–1.5)a | 0.2 (0.0–0.8)a | 0.4 (0.1–2.5)a | 0.4 (0.2–1.0)a | 0.1 (0.0–1.0)ᵃ | 0.2 (0.1–1.1)a |
Fluticasone and salmeterol | 0.1 (0.1–0.3)a | 0.0 | 0.1 (0.0–0.8)a | 0.0 | 0.4 (0.2–0.8)a | 0.3 (0.1–1.5)a | 0.0 |
Antihistamines | 1.8 (1.3–2.6) | 0.9 (0.3–2.6)a | 1.4 (0.7–2.7)a | 2.1 (1.1–4.0)a | 3.2 (2.1–5.0) | 1.0 (0.7–1.7) | 2.0 (0.8–5.0)a |
Cetirizine | 1.0 (0.6–1.6) | 0.9 (0.3–2.6)a | 0.8 (0.5–1.4) | 0.9 (0.4–2.3)a | 1.3 (0.7–2.4) | 0.7 (0.4–1.4)a | 1.2 (0.3–4.2)a |
Loratadine | 0.4 (0.3–0.7) | 0.0 | 0.1 (0.0–0.7)a | 0.3 (0.1–1.4)a | 1.2 (0.7–2.0) | 0.1 (0.0–0.6)a | 0.7 (0.2–2.8)a |
Cyproheptadine | 0.2 (0.1–0.6)a | 0.0 | 0.1 (0.0–0.9)a | 0.0 | 0.8 (0.2–2.7)a | 0.1 (0.0–1.0)a | 0.0 |
Leukotriene modifiers | 1.7 (1.3–2.2) | 0.3 (0.1–1.0)a | 0.8 (0.4–1.7)a** | 0.9 (0.4–1.9)a | 4.0 (2.5–6.4)** | 1.9 (1.1–3.1) | 1.8 (0.8–3.7)a |
Montelukast | 1.7 (1.3–2.2) | 0.3 (0.1–1.0)a | 0.8 (0.4–1.7)a** | 0.9 (0.4–1.9)a | 4.0 (2.5–6.4)** | 1.9 (1.1–3.1) | 1.8 (0.8–3.7)a |
Respiratory inhalant products | 1.3 (0.8–1.9) | 0.4 (0.1–1.5)a | 1.3 (0.6–3.0)a | 1.0 (0.4–2.4)a | 3.1 (2.1–4.5) | 0.2 (0.0–1.0)a | 1.4 (0.5–3.7)a |
Beclomethasone | 0.5 (0.3–0.9) | 0.1 (0.0–0.6)a | 0.7 (0.2–2.4)a | 0.4 (0.1–1.1)a | 1.2 (0.5–2.4)a* | 0.1 (0.0–1.0)a | 0.6 (0.1–3.1)a |
Fluticasone | 0.7 (0.4–1.2) | 0.3 (0.1–1.1)a | 0.6 (0.2–1.9)a | 0.6 (0.2–1.6)a | 1.6 (0.9–2.7) | 0.1 (0.0–0.7)a | 0.7 (0.2–2.8)a |
Psychotherapeutic agentsb | 5.0 (4.0–6.3) | 0.1 (0.0–0.6)a | 1.5 (0.5–5.0)a | 3.5 (1.8–6.7)a | 10.9 (8.7–13.6)** | 6.4 (4.1–9.9) | 5.7 (3.4–9.5) |
CNS stimulants | 3.3 (2.5–4.4) | 0.1 (0.0–0.6)a | 1.1 (0.3–4.3)a | 2.2 (1.2–4.1) | 9.4 (7.2–12.0)** | 1.6 (0.9–3.0) | 4.3 (2.3–7.9)** |
Methylphenidate | 1.6 (1.0–2.4) | 0.1 (0.0–0.6)a | 0.2 (0.0–1.5)a | 0.5 (0.1–2.5)a | 5.2 (3.2–8.3)** | 0.8 (0.2–2.9)a | 1.8 (0.8–3.9)a |
Lisdexamfetamine | 0.7 (0.5–1.0) | 0.0 | 0.0 | 0.8 (0.2–2.8)a | 1.7 (1.0–3.2) | 0.1 (0.0–1.0)a | 1.1 (0.4–2.8)a |
Amphetamine and dextroamphetamine | 0.4 (0.2–0.9)a | 0.0 | 0.6 (0.1–5.1)a | 0.3 (0.1–1.5)a | 0.9 (0.4–2.0)a | 0.3 (0.1–1.0)a | 0.4 (0.1–2.1)a |
Antidepressants | 1.2 (0.7–2.0) | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 1.3 (0.5–3.5)a* | 3.8 (1.9–7.6)a | 1.3 (0.5–3.7)a** |
Fluoxetine | 0.3 (0.2–0.6) | 0.0 | 0.0 | 0.0 | 0.5 (0.2–1.6)a | 0.7 (0.2–2.1)a | 0.5 (0.2–1.6)a |
Escitalopram | 0.2 (0.1–0.9)a | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 (0.1–4.9)a | 0.5 (0.1–3.9)a |
Trazodone | 0.2 (0.0–0.8)a | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 0.0 | 0.9 (0.2–4.6)a | 0.0 |
Antipsychotics | 0.9 (0.7–1.1) | 0.0 | 0.0 | 0.8 (0.3–2.7)a | 1.9 (1.1–3.3)* | 1.2 (0.6–2.5)a | 1.1 (0.3–3.3)a |
Aripiprazole | 0.2 (0.1–0.5)a | 0.0 | 0.0 | 0.0 | 0.5 (0.3–0.7) | 0.4 (0.1–1.7)a | 0.4 (0.1–3.3)a |
Risperidone | 0.4 (0.3–0.7) | 0.0 | 0.0 | 0.8 (0.3–2.7)a | 0.9 (0.3–3.1)a | 0.1 (0.0–0.9)a | 0.6 (0.2–2.5)a |
Quetiapine | 0.2 (0.1–0.4) | 0.0 | 0.0 | 0.0 | 0.7 (0.4–1.1) | 0.5 (0.2–1.9)a | 0.0 |
Anticonvulsants | 0.8 (0.3–1.9)a | 0.0 | 0.2 (0.0–1.5)a | 1.0 (0.3–3.6)a | 0.4 (0.1–1.4)a | 1.7 (0.5–5.6)a | 1.2 (0.4–3.8)a |
Topiramate | 0.3 (0.1–1.1)a | 0.0 | 0.2 (0.0–1.5)a | 0.3 (0.2–0.5) | 0.0 | 1.1 (0.2–6.7)a | 0.3 (0.1–1.5)a |
Lamotrigine | 0.3 (0.1–0.9)a | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 (0.2–4.6)a | 0.6 (0.1–3.4)a |
Divalproex sodium | 0.1 (0.0–0.5)a | 0.0 | 0.0 | 0.0 | 0.2 (0.0–1.7)a | 0.2 (0.0–1.3)a | 0.2 (0.0–1.1)ᵃ |
Anxiolytics, sedatives, and hypnotics | 0.3 (0.2–0.4) | 0.0 | 0.3 (0.0–2.4)a | 0.2 (0.1–0.4)a | 0.1 (0.0–0.4)a | 0.8 (0.2–2.9)a | 0.2 (0.0–1.2)a** |
Hydroxyzine | 0.2 (0.1–0.4) | 0.0 | 0.3 (0.0–2.4)a | 0.2 (0.1–0.4)a | 0.1 (0.0–0.4)a | 0.7 (0.2–3.1)a | 0.1 (0.0–0.9)a |
Antibiotics | 4.8 (3.7–6.2) | 7.0 (5.2–9.4) | 5.8 (4.5–7.4) | 3.0 (1.6–5.6) | 3.5 (2.0–6.1)* | 6.6 (3.6–11.7) | 3.5 (2.0–6.0)** |
Penicillins | 2.2 (1.6–3.0) | 4.5 (3.3–6.1) | 3.1 (2.2–4.4) | 1.1 (0.5–2.6)a | 1.4 (0.7–2.8)a | 2.6 (1.1–6.0)a | 1.1 (0.3–3.8)a** |
Amoxicillin | 1.8 (1.4–2.4) | 4.4 (3.2–6.1) | 2.9 (2.0–4.3) | 0.6 (0.2–1.6)a | 1.4 (0.7–2.8)a | 1.1 (0.6–2.0) | 1.1 (0.3–3.8)a |
Macrolide derivatives | 0.8 (0.5–1.4) | 0.2 (0.0–1.0)a | 1.0 (0.4–2.3)a | 1.2 (0.4–3.8)a | 1.4 (0.5–3.6)a | 0.9 (0.3–2.8)a | 0.2 (0.0–1.0)a* |
Azithromycin | 0.8 (0.5–1.2) | 0.2 (0.0–1.0)a | 0.9 (0.4–2.1)a | 1.2 (0.4–3.8)a | 1.4 (0.5–3.6)a | 0.5 (0.1–2.9)a | 0.2 (0.0–1.0)a |
Cephalosporins | 0.5 (0.2–1.3)a | 0.7 (0.2–3.1)a | 0.9 (0.3–2.7)a | 0.2 (0.0–1.1)a | 0.3 (0.0–2.3)a | 0.6 (0.1–4.9)a | 0.5 (0.1–2.8)a |
Cefdinir | 0.2 (0.1–0.6)a | 0.2 (0.0–1.3)a | 0.2 (0.1–0.8)a | 0.1 (0.0–1.2)a | 0.3 (0.0–2.3)a | 0.0 | 0.4 (0.1–3.3)a |
Topical agents | 3.0 (2.5–3.5) | 1.2 (0.6–2.3) | 1.7 (1.0–2.9) | 1.9 (1.0–3.5) | 4.9 (3.2–7.5) | 3.7 (1.8–7.4)a | 3.7 (1.7–8.0)a |
Nasal preparations | 1.5 (1.0–2.3) | 0.1 (0.0–1.3)a | 0.7 (0.3–1.5)a | 0.5 (0.2–1.3)a | 4.2 (2.5–7.1)** | 0.8 (0.2–3.1)a | 2.0 (0.7–5.5)a |
Fluticasone nasal | 1.0 (0.6–1.7) | 0.0 | 0.3 (0.1–1.6)a | 0.3 (0.1–1.2)a | 2.4 (1.1–4.9)a* | 0.6 (0.1–3.0)a | 2.0 (0.7–5.5)a |
Mometasone nasal | 0.5 (0.2–0.9)a | 0.1 (0.0–1.3)a | 0.2 (0.0–1.4)a | 0.1 (0.0–0.7)a | 1.7 (0.7–4.3)a* | 0.2 (0.0–2.0)a | 0.2 (0.0–0.7)a |
Dermatological agents | 1.2 (0.7–1.9) | 0.5 (0.2–1.2)a | 0.6 (0.2–1.5)a | 1.4 (0.7–3.0)a | 0.7 (0.3–1.7)a** | 2.8 (1.1–6.9)a | 0.9 (0.2–3.1)a |
Tretinoin topical | 0.2 (0.1–0.7)a | 0.0 | 0.0 | 0.1 (0.0–1.0)a | 0.0 | 0.7 (0.1–4.4)a | 0.3 (0.0–2.6)a |
Hormones or hormone modifiers | 2.1 (1.5–2.8) | 1.0 (0.5–2.1)a | 1.1 (0.5–2.6)a** | 1.2 (0.5–2.5)a | 0.9 (0.2–3.3)a | 7.2 (5.3–9.5) | 0.7 (0.2–2.1)a** |
Contraceptivesc | 2.5 (1.8–3.5) | 0.0 | 0.0 | 0.0 | 0.0 | 7.0 (5.2–9.3) | 0.0 |
Ethinyl estradiol–norethindronec | 0.9 (0.4–2.1)a | 0.0 | 0.0 | 0.0 | 0.0 | 2.5 (1.1–5.6)a | 0.0 |
Adrenal cortical steroids | 0.6 (0.4–1.0) | 1.0 (0.5–2.1)a | 0.9 (0.4–2.2)a** | 0.7 (0.2–2.4)a | 0.4 (0.1–1.8)a | 0.2 (0.0–1.0)a | 0.6 (0.2–2.0)a** |
Budesonide | 0.3 (0.2–0.7)a | 0.5 (0.2–1.6)a | 0.4 (0.2–1.2)a | 0.5 (0.1–2.6)a | 0.4 (0.1–1.9)a | 0.1 (0.0–1.0)a | 0.1 (0.0–1.0)a |
Gastrointestinal agents | 1.5 (0.8–2.6) | 1.7 (1.0–3.0) | 1.6 (0.9–2.6) | 1.0 (0.4–2.7)a | 1.4 (0.5–3.9)a | 2.0 (0.8–4.9)a | 1.3 (0.4–3.7)a** |
PPIs | 0.6 (0.3–1.3)a | 0.2 (0.0–0.9)a | 0.5 (0.2–1.3)a | 0.1 (0.0–0.7)a | 0.6 (0.1–2.8)a | 1.1 (0.4–3.1)a | 1.0 (0.2–4.6)a |
Omeprazole | 0.3 (0.1–1.2)a | 0.1 (0.0–1.0)a | 0.1 (0.0–0.6)a | 0.1 (0.0–0.7)a | 0.6 (0.1–2.8)a | 0.1 (0.0–0.8)a | 0.9 (0.2–4.8)a |
H2 antagonist | 0.5 (0.3–1.0)a | 1.4 (0.7–3.1)a | 1.0 (0.6–1.9) | 0.5 (0.1–2.1)a | 0.3 (0.1–1.2)a | 0.2 (0.0–1.3)a | 0.1 (0.0–0.8)a** |
Ranitidine | 0.5 (0.3–1.0)a | 1.4 (0.6–3.1)a | 1.0 (0.6–1.9) | 0.5 (0.1–2.1)a | 0.3 (0.1–1.2)a | 0.2 (0.0–1.3)a | 0.1 (0.0–0.8)a |
Antiadrenergic agents, centrally acting | 1.1 (0.8–1.6) | 0.0 | 0.2 (0.0–1.3)a | 1.1 (0.3–3.5)a | 3.3 (1.9–5.7)** | 0.2 (0.0–1.9)a | 1.4 (0.5–4.1)a** |
Clonidine | 0.8 (0.5–1.3) | 0.0 | 0.2 (0.0–1.3)a | 1.0 (0.3–3.5)a | 2.1 (0.8–5.0)a | 0.2 (0.0–1.9)a | 0.9 (0.2–4.5)a |
Guanfacine | 0.4 (0.2–0.9)a | 0.0 | 0.0 | 0.2 (0.0–0.8)a | 1.5 (0.6–3.6)a** | 0.0 | 0.5 (0.1–2.3)a |
Analgesics | 1.1 (0.7–1.6) | 0.2 (0.0–0.8)a | 1.0 (0.4–2.3)a | 0.6 (0.2–1.9)a | 0.2 (0.0–0.7)a | 3.2 (1.6–6.4)a | 1.2 (0.6–2.3)a* |
Nonsteroidal anti- inflammatory agents | 0.7 (0.4–1.2) | 0.2 (0.0–0.8)a | 0.9 (0.4–2.2)a* | 0.3 (0.1–1.1)a | 0.0 | 1.8 (0.8–4.2)a | 1.0 (0.5–2.2)a |
Diclofenac | 0.1 (0.0–0.8)a | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 (0.1–4.9)a | 0.1 (0.0–0.7)a |
Narcotics | 0.4 (0.2–0.8) | 0.0 | 0.1 (0.0–0.6)a* | 0.5 (0.1–1.8)a | 0.2 (0.0–0.7)a | 1.5 (0.7–3.5)a | 0.2 (0.0–0.9)a** |
Hydrocodone | 0.3 (0.2–0.7)a | 0.0 | 0.1 (0.0–0.6)a | 0.2 (0.0–1.0)a | 0.1 (0.0–0.8)a | 1.3 (0.5–3.4)a | 0.2 (0.0–0.9)a |
Oxycodone | 0.2 (0.1–0.5)a | 0.0 | 0.0 | 0.3 (0.0–2.2)a | 0.0 | 0.8 (0.3–2.6)a | 0.0 |
Antiemetic agents | 0.7 (0.5–1.1) | 0.5 (0.1–1.6)a | 1.1 (0.3–3.3)a | 0.8 (0.3–2.4)a | 0.2 (0.1–0.6)a | 1.6 (0.8–3.3)a | 0.1 (0.0–1.2)a |
Ondansetron | 0.5 (0.3–0.8) | 0.1 (0.0–1.1)a | 0.7 (0.2–2.8)a | 0.5 (0.1–2.3)a | 0.1 (0.0–0.5)a | 1.1 (0.4–3.2)a | 0.1 (0.0–1.2)a |
Diphenhydramine | 0.2 (0.1–0.3)a | 0.2 (0.0–0.8)a | 0.0 | 0.1 (0.0–1.2)a | 0.2 (0.0–0.8)a | 0.5 (0.2–1.6)a | 0.0 |
Promethazine | 0.1 (0.0–0.4)a | 0.1 (0.0–0.9)a | 0.4 (0.1–1.8)a* | 0.1 (0.0–1.0)a | 0.0 | 0.0 | 0.0 |
Antidiabetic agents | 0.5 (0.2–1.2)a | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 1.3 (0.3–5.2)a | 1.4 (0.5–3.7)a | 0.1 (0.0–1.0)a |
Metformin | 0.2 (0.1–0.6)a | 0.0 | 0.0 | 0.0 | 0.1 (0.0–0.4)a | 1.1 (0.3–3.7)a | 0.0 |
Insulin | 0.3 (0.1–0.8)a | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 1.2 (0.3–5.3)a* | 0.3 (0.1–0.6)a | 0.1 (0.0–1.0)a |
. | Prevalence of Use, % (95% CI) . | ||||||
---|---|---|---|---|---|---|---|
Overall, n = 4404 . | 0–5 y . | 6–12 y . | 13–19 y . | ||||
Girls (n = 775) . | Boys (n = 828) . | Girls (n = 746) . | Boys (n = 817) . | Girls (n = 640) . | Boys (n = 598) . | ||
Respiratory agents | 6.8 (5.8–8.0) | 3.9 (2.3–6.6) | 5.1 (3.3–7.8)** | 5.7 (4.1–8.0) | 11.5 (8.9–14.7)* | 6.4 (4.2–9.7) | 7.0 (4.9–9.9) |
Bronchodilators | 3.5 (3.0–4.1) | 2.7 (1.5–4.7) | 2.7 (1.5–4.8) | 3.0 (1.7–5.5) | 5.5 (4.3–6.9)* | 3.4 (1.7–7.0)a | 3.2 (2.1–5.0) |
Albuterol | 3.0 (2.5–3.6) | 2.6 (1.5–4.5) | 2.5 (1.4–4.5) | 2.6 (1.4–4.8) | 4.5 (3.1–6.6) | 3.1 (1.4–6.9)a | 2.6 (1.8–3.6) |
Levalbuterol | 0.3 (0.1–0.6)a | 0.2 (0.0–1.5)a | 0.2 (0.0–0.8)a | 0.4 (0.1–2.5)a | 0.4 (0.2–1.0)a | 0.1 (0.0–1.0)ᵃ | 0.2 (0.1–1.1)a |
Fluticasone and salmeterol | 0.1 (0.1–0.3)a | 0.0 | 0.1 (0.0–0.8)a | 0.0 | 0.4 (0.2–0.8)a | 0.3 (0.1–1.5)a | 0.0 |
Antihistamines | 1.8 (1.3–2.6) | 0.9 (0.3–2.6)a | 1.4 (0.7–2.7)a | 2.1 (1.1–4.0)a | 3.2 (2.1–5.0) | 1.0 (0.7–1.7) | 2.0 (0.8–5.0)a |
Cetirizine | 1.0 (0.6–1.6) | 0.9 (0.3–2.6)a | 0.8 (0.5–1.4) | 0.9 (0.4–2.3)a | 1.3 (0.7–2.4) | 0.7 (0.4–1.4)a | 1.2 (0.3–4.2)a |
Loratadine | 0.4 (0.3–0.7) | 0.0 | 0.1 (0.0–0.7)a | 0.3 (0.1–1.4)a | 1.2 (0.7–2.0) | 0.1 (0.0–0.6)a | 0.7 (0.2–2.8)a |
Cyproheptadine | 0.2 (0.1–0.6)a | 0.0 | 0.1 (0.0–0.9)a | 0.0 | 0.8 (0.2–2.7)a | 0.1 (0.0–1.0)a | 0.0 |
Leukotriene modifiers | 1.7 (1.3–2.2) | 0.3 (0.1–1.0)a | 0.8 (0.4–1.7)a** | 0.9 (0.4–1.9)a | 4.0 (2.5–6.4)** | 1.9 (1.1–3.1) | 1.8 (0.8–3.7)a |
Montelukast | 1.7 (1.3–2.2) | 0.3 (0.1–1.0)a | 0.8 (0.4–1.7)a** | 0.9 (0.4–1.9)a | 4.0 (2.5–6.4)** | 1.9 (1.1–3.1) | 1.8 (0.8–3.7)a |
Respiratory inhalant products | 1.3 (0.8–1.9) | 0.4 (0.1–1.5)a | 1.3 (0.6–3.0)a | 1.0 (0.4–2.4)a | 3.1 (2.1–4.5) | 0.2 (0.0–1.0)a | 1.4 (0.5–3.7)a |
Beclomethasone | 0.5 (0.3–0.9) | 0.1 (0.0–0.6)a | 0.7 (0.2–2.4)a | 0.4 (0.1–1.1)a | 1.2 (0.5–2.4)a* | 0.1 (0.0–1.0)a | 0.6 (0.1–3.1)a |
Fluticasone | 0.7 (0.4–1.2) | 0.3 (0.1–1.1)a | 0.6 (0.2–1.9)a | 0.6 (0.2–1.6)a | 1.6 (0.9–2.7) | 0.1 (0.0–0.7)a | 0.7 (0.2–2.8)a |
Psychotherapeutic agentsb | 5.0 (4.0–6.3) | 0.1 (0.0–0.6)a | 1.5 (0.5–5.0)a | 3.5 (1.8–6.7)a | 10.9 (8.7–13.6)** | 6.4 (4.1–9.9) | 5.7 (3.4–9.5) |
CNS stimulants | 3.3 (2.5–4.4) | 0.1 (0.0–0.6)a | 1.1 (0.3–4.3)a | 2.2 (1.2–4.1) | 9.4 (7.2–12.0)** | 1.6 (0.9–3.0) | 4.3 (2.3–7.9)** |
Methylphenidate | 1.6 (1.0–2.4) | 0.1 (0.0–0.6)a | 0.2 (0.0–1.5)a | 0.5 (0.1–2.5)a | 5.2 (3.2–8.3)** | 0.8 (0.2–2.9)a | 1.8 (0.8–3.9)a |
Lisdexamfetamine | 0.7 (0.5–1.0) | 0.0 | 0.0 | 0.8 (0.2–2.8)a | 1.7 (1.0–3.2) | 0.1 (0.0–1.0)a | 1.1 (0.4–2.8)a |
Amphetamine and dextroamphetamine | 0.4 (0.2–0.9)a | 0.0 | 0.6 (0.1–5.1)a | 0.3 (0.1–1.5)a | 0.9 (0.4–2.0)a | 0.3 (0.1–1.0)a | 0.4 (0.1–2.1)a |
Antidepressants | 1.2 (0.7–2.0) | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 1.3 (0.5–3.5)a* | 3.8 (1.9–7.6)a | 1.3 (0.5–3.7)a** |
Fluoxetine | 0.3 (0.2–0.6) | 0.0 | 0.0 | 0.0 | 0.5 (0.2–1.6)a | 0.7 (0.2–2.1)a | 0.5 (0.2–1.6)a |
Escitalopram | 0.2 (0.1–0.9)a | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 (0.1–4.9)a | 0.5 (0.1–3.9)a |
Trazodone | 0.2 (0.0–0.8)a | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 0.0 | 0.9 (0.2–4.6)a | 0.0 |
Antipsychotics | 0.9 (0.7–1.1) | 0.0 | 0.0 | 0.8 (0.3–2.7)a | 1.9 (1.1–3.3)* | 1.2 (0.6–2.5)a | 1.1 (0.3–3.3)a |
Aripiprazole | 0.2 (0.1–0.5)a | 0.0 | 0.0 | 0.0 | 0.5 (0.3–0.7) | 0.4 (0.1–1.7)a | 0.4 (0.1–3.3)a |
Risperidone | 0.4 (0.3–0.7) | 0.0 | 0.0 | 0.8 (0.3–2.7)a | 0.9 (0.3–3.1)a | 0.1 (0.0–0.9)a | 0.6 (0.2–2.5)a |
Quetiapine | 0.2 (0.1–0.4) | 0.0 | 0.0 | 0.0 | 0.7 (0.4–1.1) | 0.5 (0.2–1.9)a | 0.0 |
Anticonvulsants | 0.8 (0.3–1.9)a | 0.0 | 0.2 (0.0–1.5)a | 1.0 (0.3–3.6)a | 0.4 (0.1–1.4)a | 1.7 (0.5–5.6)a | 1.2 (0.4–3.8)a |
Topiramate | 0.3 (0.1–1.1)a | 0.0 | 0.2 (0.0–1.5)a | 0.3 (0.2–0.5) | 0.0 | 1.1 (0.2–6.7)a | 0.3 (0.1–1.5)a |
Lamotrigine | 0.3 (0.1–0.9)a | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 (0.2–4.6)a | 0.6 (0.1–3.4)a |
Divalproex sodium | 0.1 (0.0–0.5)a | 0.0 | 0.0 | 0.0 | 0.2 (0.0–1.7)a | 0.2 (0.0–1.3)a | 0.2 (0.0–1.1)ᵃ |
Anxiolytics, sedatives, and hypnotics | 0.3 (0.2–0.4) | 0.0 | 0.3 (0.0–2.4)a | 0.2 (0.1–0.4)a | 0.1 (0.0–0.4)a | 0.8 (0.2–2.9)a | 0.2 (0.0–1.2)a** |
Hydroxyzine | 0.2 (0.1–0.4) | 0.0 | 0.3 (0.0–2.4)a | 0.2 (0.1–0.4)a | 0.1 (0.0–0.4)a | 0.7 (0.2–3.1)a | 0.1 (0.0–0.9)a |
Antibiotics | 4.8 (3.7–6.2) | 7.0 (5.2–9.4) | 5.8 (4.5–7.4) | 3.0 (1.6–5.6) | 3.5 (2.0–6.1)* | 6.6 (3.6–11.7) | 3.5 (2.0–6.0)** |
Penicillins | 2.2 (1.6–3.0) | 4.5 (3.3–6.1) | 3.1 (2.2–4.4) | 1.1 (0.5–2.6)a | 1.4 (0.7–2.8)a | 2.6 (1.1–6.0)a | 1.1 (0.3–3.8)a** |
Amoxicillin | 1.8 (1.4–2.4) | 4.4 (3.2–6.1) | 2.9 (2.0–4.3) | 0.6 (0.2–1.6)a | 1.4 (0.7–2.8)a | 1.1 (0.6–2.0) | 1.1 (0.3–3.8)a |
Macrolide derivatives | 0.8 (0.5–1.4) | 0.2 (0.0–1.0)a | 1.0 (0.4–2.3)a | 1.2 (0.4–3.8)a | 1.4 (0.5–3.6)a | 0.9 (0.3–2.8)a | 0.2 (0.0–1.0)a* |
Azithromycin | 0.8 (0.5–1.2) | 0.2 (0.0–1.0)a | 0.9 (0.4–2.1)a | 1.2 (0.4–3.8)a | 1.4 (0.5–3.6)a | 0.5 (0.1–2.9)a | 0.2 (0.0–1.0)a |
Cephalosporins | 0.5 (0.2–1.3)a | 0.7 (0.2–3.1)a | 0.9 (0.3–2.7)a | 0.2 (0.0–1.1)a | 0.3 (0.0–2.3)a | 0.6 (0.1–4.9)a | 0.5 (0.1–2.8)a |
Cefdinir | 0.2 (0.1–0.6)a | 0.2 (0.0–1.3)a | 0.2 (0.1–0.8)a | 0.1 (0.0–1.2)a | 0.3 (0.0–2.3)a | 0.0 | 0.4 (0.1–3.3)a |
Topical agents | 3.0 (2.5–3.5) | 1.2 (0.6–2.3) | 1.7 (1.0–2.9) | 1.9 (1.0–3.5) | 4.9 (3.2–7.5) | 3.7 (1.8–7.4)a | 3.7 (1.7–8.0)a |
Nasal preparations | 1.5 (1.0–2.3) | 0.1 (0.0–1.3)a | 0.7 (0.3–1.5)a | 0.5 (0.2–1.3)a | 4.2 (2.5–7.1)** | 0.8 (0.2–3.1)a | 2.0 (0.7–5.5)a |
Fluticasone nasal | 1.0 (0.6–1.7) | 0.0 | 0.3 (0.1–1.6)a | 0.3 (0.1–1.2)a | 2.4 (1.1–4.9)a* | 0.6 (0.1–3.0)a | 2.0 (0.7–5.5)a |
Mometasone nasal | 0.5 (0.2–0.9)a | 0.1 (0.0–1.3)a | 0.2 (0.0–1.4)a | 0.1 (0.0–0.7)a | 1.7 (0.7–4.3)a* | 0.2 (0.0–2.0)a | 0.2 (0.0–0.7)a |
Dermatological agents | 1.2 (0.7–1.9) | 0.5 (0.2–1.2)a | 0.6 (0.2–1.5)a | 1.4 (0.7–3.0)a | 0.7 (0.3–1.7)a** | 2.8 (1.1–6.9)a | 0.9 (0.2–3.1)a |
Tretinoin topical | 0.2 (0.1–0.7)a | 0.0 | 0.0 | 0.1 (0.0–1.0)a | 0.0 | 0.7 (0.1–4.4)a | 0.3 (0.0–2.6)a |
Hormones or hormone modifiers | 2.1 (1.5–2.8) | 1.0 (0.5–2.1)a | 1.1 (0.5–2.6)a** | 1.2 (0.5–2.5)a | 0.9 (0.2–3.3)a | 7.2 (5.3–9.5) | 0.7 (0.2–2.1)a** |
Contraceptivesc | 2.5 (1.8–3.5) | 0.0 | 0.0 | 0.0 | 0.0 | 7.0 (5.2–9.3) | 0.0 |
Ethinyl estradiol–norethindronec | 0.9 (0.4–2.1)a | 0.0 | 0.0 | 0.0 | 0.0 | 2.5 (1.1–5.6)a | 0.0 |
Adrenal cortical steroids | 0.6 (0.4–1.0) | 1.0 (0.5–2.1)a | 0.9 (0.4–2.2)a** | 0.7 (0.2–2.4)a | 0.4 (0.1–1.8)a | 0.2 (0.0–1.0)a | 0.6 (0.2–2.0)a** |
Budesonide | 0.3 (0.2–0.7)a | 0.5 (0.2–1.6)a | 0.4 (0.2–1.2)a | 0.5 (0.1–2.6)a | 0.4 (0.1–1.9)a | 0.1 (0.0–1.0)a | 0.1 (0.0–1.0)a |
Gastrointestinal agents | 1.5 (0.8–2.6) | 1.7 (1.0–3.0) | 1.6 (0.9–2.6) | 1.0 (0.4–2.7)a | 1.4 (0.5–3.9)a | 2.0 (0.8–4.9)a | 1.3 (0.4–3.7)a** |
PPIs | 0.6 (0.3–1.3)a | 0.2 (0.0–0.9)a | 0.5 (0.2–1.3)a | 0.1 (0.0–0.7)a | 0.6 (0.1–2.8)a | 1.1 (0.4–3.1)a | 1.0 (0.2–4.6)a |
Omeprazole | 0.3 (0.1–1.2)a | 0.1 (0.0–1.0)a | 0.1 (0.0–0.6)a | 0.1 (0.0–0.7)a | 0.6 (0.1–2.8)a | 0.1 (0.0–0.8)a | 0.9 (0.2–4.8)a |
H2 antagonist | 0.5 (0.3–1.0)a | 1.4 (0.7–3.1)a | 1.0 (0.6–1.9) | 0.5 (0.1–2.1)a | 0.3 (0.1–1.2)a | 0.2 (0.0–1.3)a | 0.1 (0.0–0.8)a** |
Ranitidine | 0.5 (0.3–1.0)a | 1.4 (0.6–3.1)a | 1.0 (0.6–1.9) | 0.5 (0.1–2.1)a | 0.3 (0.1–1.2)a | 0.2 (0.0–1.3)a | 0.1 (0.0–0.8)a |
Antiadrenergic agents, centrally acting | 1.1 (0.8–1.6) | 0.0 | 0.2 (0.0–1.3)a | 1.1 (0.3–3.5)a | 3.3 (1.9–5.7)** | 0.2 (0.0–1.9)a | 1.4 (0.5–4.1)a** |
Clonidine | 0.8 (0.5–1.3) | 0.0 | 0.2 (0.0–1.3)a | 1.0 (0.3–3.5)a | 2.1 (0.8–5.0)a | 0.2 (0.0–1.9)a | 0.9 (0.2–4.5)a |
Guanfacine | 0.4 (0.2–0.9)a | 0.0 | 0.0 | 0.2 (0.0–0.8)a | 1.5 (0.6–3.6)a** | 0.0 | 0.5 (0.1–2.3)a |
Analgesics | 1.1 (0.7–1.6) | 0.2 (0.0–0.8)a | 1.0 (0.4–2.3)a | 0.6 (0.2–1.9)a | 0.2 (0.0–0.7)a | 3.2 (1.6–6.4)a | 1.2 (0.6–2.3)a* |
Nonsteroidal anti- inflammatory agents | 0.7 (0.4–1.2) | 0.2 (0.0–0.8)a | 0.9 (0.4–2.2)a* | 0.3 (0.1–1.1)a | 0.0 | 1.8 (0.8–4.2)a | 1.0 (0.5–2.2)a |
Diclofenac | 0.1 (0.0–0.8)a | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 (0.1–4.9)a | 0.1 (0.0–0.7)a |
Narcotics | 0.4 (0.2–0.8) | 0.0 | 0.1 (0.0–0.6)a* | 0.5 (0.1–1.8)a | 0.2 (0.0–0.7)a | 1.5 (0.7–3.5)a | 0.2 (0.0–0.9)a** |
Hydrocodone | 0.3 (0.2–0.7)a | 0.0 | 0.1 (0.0–0.6)a | 0.2 (0.0–1.0)a | 0.1 (0.0–0.8)a | 1.3 (0.5–3.4)a | 0.2 (0.0–0.9)a |
Oxycodone | 0.2 (0.1–0.5)a | 0.0 | 0.0 | 0.3 (0.0–2.2)a | 0.0 | 0.8 (0.3–2.6)a | 0.0 |
Antiemetic agents | 0.7 (0.5–1.1) | 0.5 (0.1–1.6)a | 1.1 (0.3–3.3)a | 0.8 (0.3–2.4)a | 0.2 (0.1–0.6)a | 1.6 (0.8–3.3)a | 0.1 (0.0–1.2)a |
Ondansetron | 0.5 (0.3–0.8) | 0.1 (0.0–1.1)a | 0.7 (0.2–2.8)a | 0.5 (0.1–2.3)a | 0.1 (0.0–0.5)a | 1.1 (0.4–3.2)a | 0.1 (0.0–1.2)a |
Diphenhydramine | 0.2 (0.1–0.3)a | 0.2 (0.0–0.8)a | 0.0 | 0.1 (0.0–1.2)a | 0.2 (0.0–0.8)a | 0.5 (0.2–1.6)a | 0.0 |
Promethazine | 0.1 (0.0–0.4)a | 0.1 (0.0–0.9)a | 0.4 (0.1–1.8)a* | 0.1 (0.0–1.0)a | 0.0 | 0.0 | 0.0 |
Antidiabetic agents | 0.5 (0.2–1.2)a | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 1.3 (0.3–5.2)a | 1.4 (0.5–3.7)a | 0.1 (0.0–1.0)a |
Metformin | 0.2 (0.1–0.6)a | 0.0 | 0.0 | 0.0 | 0.1 (0.0–0.4)a | 1.1 (0.3–3.7)a | 0.0 |
Insulin | 0.3 (0.1–0.8)a | 0.0 | 0.0 | 0.1 (0.0–0.7)a | 1.2 (0.3–5.3)a* | 0.3 (0.1–0.6)a | 0.1 (0.0–1.0)a |
Estimates are weighted to account for differential probabilities of selection and differential nonresponse. H2, histamine2; PPI, proton pump inhibitors.
Estimates are unreliable; relative SE >30%.
Derived from Multum classification of psychotherapeutic agents, CNS stimulants, anticonvulsants, and anxiolytics, sedatives, and hypnotics.
Among girls only.
P < .01; * P < .05 by using logistic regressions to test differences between girls and boys.